In this study, we sought to evaluate the potential utility of melanoma progressionassociated genes as biomarkers for disease burden in human skin tissue samples. Based on previous microarray studies, primary genes of interest were HELLS, NCAPH, and SPINT2. 4 HELLS and NCAPH have been shown to be cell cycle activators upregulated in aggressive metastatic tumor cell lines in comparison to less-aggressive primary tumor cell lines. SPINT2 has been implicated as a tumor suppressor gene in multiple cancers; its expression induces cell apoptosis and tumor suppression in vivo.
Methods:
After defining the panel of melanoma biomarkers to evaluate, we optimized a multiplex reaction to efficiently quantify RNA for our genes of interest from small quantities of tissue. Quantitative realtime polymerase chain reaction (qRT-PCR) was performed to quantify and compare RNA levels in human skin tissue samples of nevi (n=12), primary melanoma (n=12), and metastatic melanoma (n=12). While NCAPH expression levels were difficult to measure due to minimal expression in human tissue, we were able to successfully quantify HELLS and SPINT2.
Results: HELLS expression levels were remarkably higher in metastatic melanoma compared to benign nevi (p=0.02) and primary melanoma (p=0.05) ( Figure 1A) . Meanwhile, SPINT2 expression levels were almost nonexistent in metastatic skin samples; this was evident when comparing metastatic melanoma to nevi (p=0.03) and primary melanoma (p=0.03) (Figure 1B) . There was no statistical difference between nevi and primary melanoma (p=0.11 for HELLS, p=0.31 for SPINT2).
Conclusion:
Our assay system proved sensitive in detecting differences in expression levels of HELLS and SPINT2 in metastatic melanoma compared to benign nevi and primary melanoma. Such novel biomarkers help us further understand the biology of melanoma, with potential clinical implications in prognosis, therapy, and detection of treatment response and tumor recurrence. 
